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Abstract
Introduction: Differentiating between sterile inflammation and bacterial infection in critically ill patients with fever
and other signs of the systemic inflammatory response syndrome (SIRS) remains a clinical challenge. The objective
of our study was to mine an existing genome-wide expression database for the discovery of candidate diagnostic
biomarkers to predict the presence of bacterial infection in critically ill children.
Methods: Genome-wide expression data were compared between patients with SIRS having negative bacterial
cultures (n = 21) and patients with sepsis having positive bacterial cultures (n = 60). Differentially expressed genes
were subjected to a leave-one-out cross-validation (LOOCV) procedure to predict SIRS or sepsis classes. Serum
concentrations of interleukin-27 (IL-27) and procalcitonin (PCT) were compared between 101 patients with SIRS and
130 patients with sepsis. All data represent the first 24 hours of meeting criteria for either SIRS or sepsis.
Results: Two hundred twenty one gene probes were differentially regulated between patients with SIRS and
patients with sepsis. The LOOCV procedure correctly predicted 86% of the SIRS and sepsis classes, and Epstein-Barr
virus-induced gene 3 (EBI3) had the highest predictive strength. Computer-assisted image analyses of gene-
expression mosaics were able to predict infection with a specificity of 90% and a positive predictive value of 94%.
Because EBI3 is a subunit of the heterodimeric cytokine, IL-27, we tested the ability of serum IL-27 protein
concentrations to predict infection. At a cut-point value of ≥5 ng/ml, serum IL-27 protein concentrations predicted
infection with a specificity and a positive predictive value of >90%, and the overall performance of IL-27 was
generally better than that of PCT. A decision tree combining IL-27 and PCT improved overall predictive capacity
compared with that of either biomarker alone.
Conclusions: Genome-wide expression analysis has provided the foundation for the identification of IL-27 as a
novel candidate diagnostic biomarker for predicting bacterial infection in critically ill children. Additional studies
will be required to test further the diagnostic performance of IL-27.
The microarray data reported in this article have been deposited in the Gene Expression Omnibus under accession
number GSE4607.
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Introduction
Differentiating between sterile inflammation and bacter-
ial infection in critically ill patients with fever and other
signs of the systemic inflammatory response syndrome
(SIRS) remains a clinical challenge [1-3]. Standard micro-
biology culture techniques remain the gold standard, but
they can lack sensitivity, and often, a substantial delay
occurs between obtaining cultures and generating clini-
cally useful data. Consequently, a great deal of interest
exists in developing biomarkers to differentiate sepsis
from noninfectious causes of SIRS before microbiology
data become available [4].
We generated a large genome-wide expression database
(transcriptomics) of critically ill children with SIRS, sep-
sis, and septic shock by way of microarray technology
[5-18]. In the current study, we mined these data to dis-
cover gene signatures having the potential to differentiate
sepsis from noninfectious causes of SIRS. Herein we
report that interleukin-27 (IL-27) may represent a novel
diagnostic biomarker for predicting bacterial infection in
critically ill patients.
Materials and methods
Patients and data collection
The study protocol was approved by the Institutional
Review Boards of each participating institution (n = 17)
and was previously described in detail [14,18]. In brief,
children 10 years of age or younger admitted to the pedia-
tric intensive care unit (PICU) and meeting pediatric-spe-
cific criteria for SIRS, sepsis, or septic shock were eligible
for enrollment [19]. After informed consent from parents
or legal guardians, we obtained blood samples within 24
hours of initial presentation to the PICU with SIRS, sepsis,
or septic shock. Clinical and laboratory data were collected
daily while patients were in the PICU, and stored by using
a Web-based database. Mortality was tracked for 28 days
after enrollment, and organ-failure data were based on
pediatric-specific criteria [19]. Control samples were
obtained from healthy children in the ambulatory depart-
ments of participating institutions by using previously
published inclusion and exclusion criteria [18].
All patients with microarray data in the current study
were previously reported in studies addressing hypotheses
entirely different from that of the current report
[7,9-16,18,20]. For the current study, all patients in the sep-
sis and septic-shock cohorts had clinical microbiology
laboratory confirmation of a bacterial pathogen from blood
cultures or other normally sterile body fluids, whereas all
patients in the SIRS cohort had negative bacterial cultures.
RNA extraction, microarray hybridization, and microarray
analysis
Total RNA was isolated from whole-blood samples by
using the PaxGene Blood RNA System (PreAnalytiX;
Qiagen/Becton Dickinson, Valencia, CA, USA) accord-
ing the manufacturer’s specifications. Microarray hybri-
dization was performed by the Affymetrix Gene Chip
Core facility at Cincinnati Children’s Hospital Research
Foundation, as previously described, by using the
Human Genome U133 Plus 2.0 GeneChip (Affymetrix,
Santa Clara, CA, USA) [18].
Analyses were performed by using one patient sample
per chip. Image files were captured by using an Affyme-
trix GeneChip Scanner 3000. Raw data files were subse-
quently preprocessed by using Robust Multiple-array
Average (RMA) normalization with GeneSpring GX 7.3
software (Agilent Technologies, Palo Alto, CA, USA)
[21]. All chips were then normalized to the respective
median values of normal, age-matched controls, as pre-
viously described [18]. Differences in mRNA abundance
between patient samples were determined by using
GeneSpring GX 7.3. All statistical analyses used correc-
tions for multiple comparisons. The specific statistical
and filtering approaches for identifying differentially
regulated genes are provided in the Results section
because of their relevance to data interpretation. All
microarray data have been deposited in the Gene Expres-
sion Omnibus [22] under accession number GSE4607.
Generation of gene-expression mosaics
Gene-expression mosaics were generated by using the
Gene Expression Dynamics Inspector (GEDI) platform.
GEDI is a publicly available gene-expression analysis
program developed by the Ingber Laboratory at Harvard
University [23,24]. The signature graphic outputs of
GEDI are gene-expression mosaics that give microarray
data a “face” that is intuitively recognizable by human
pattern recognition [10,11]. The underlying algorithm
for creating the mosaics is a self-organizing map (SOM).
Computer-assisted image analysis
Individual patient mosaics were compared with SIRS
and sepsis reference mosaics by using a publicly avail-
able image-analysis platform (ImageJ), as previously
described [10]. In brief, the absolute difference in RGB
pixel-to-pixel intensity was calculated for each individual
patient mosaic relative to the SIRS and sepsis reference
mosaics. Final classification was based on the “least dif-
ference” between the individual patient mosaic and the
two reference mosaics.
Measurement of IL-27 and procalcitonin serum protein
concentrations
Serum IL-27 (EMD Millipore Corporation, Billerica,
MA, USA) and procalcitonin (Bio-Rad, Hercules, CA,
USA) protein concentrations were measured by using a
magnetic bead multiplex platform and a Luminex 100/
200 System (Luminex Corporation, Austin, TX, USA),
according the manufacturers’ specifications.
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Statistical analysis
Initially, data are described by using medians, interquar-
tile ranges (IQRs), and percentages. Comparisons
between study cohorts used the Mann-Whitney U test,
c2, or Fisher Exact tests, as appropriate. Descriptive sta-
tistics and comparisons used SigmaStat Software (Systat
Software, Inc., San Jose, CA, USA). Classification and
regression tree (CART) analysis was conducted by using
the Salford Predictive Modeler v6.6 (Salford Systems,
San Diego, CA, USA) [25]. Biomarker test characteristics
are reported by using diagnostic test statistics with 95%
confidence intervals computed by using the score
method, as implemented by VassarStats Website for Sta-
tistical Computation [26].
Results
Initial identification of candidate sepsis diagnostic genes
Candidate sepsis diagnostic genes were identified by ana-
lyzing existing patients in our genome-wide expression
database of critically ill children meeting criteria for
either SIRS with negative bacterial cultures (n = 21) or
sepsis with positive bacterial cultures (n = 60). All gene-
expression data reflect the first 24 hours of meeting clini-
cal criteria for SIRS or sepsis. Fifty-three of the patients
with sepsis also met criteria for septic shock. The basic
clinical and demographic characteristics of the SIRS and
sepsis cohorts are shown in Table 1. Patients in the sepsis
cohort were younger and had a higher PRISM score com-
pared with patients in the SIRS cohort.
The initial step for identifying candidate sepsis diag-
nostic genes consisted of an expression filter. Starting
with all gene probes on the array (>80,000), we selected
gene probes having ≥2-fold expression between the
median values of patients with sepsis and patients with
SIRS, respectively. This expression filter yielded 228
gene probes. We next subjected the 228 gene probes to
a statistical test (ANOVA with a Benjamini-Hochberg
false-discovery rate of 5%) by using the sepsis and SIRS
cohorts as the comparison groups. This statistical test
yielded 221 gene probes differentially regulated between
patients with sepsis and patients with SIRS.
We then performed a leave-one-out cross-validation
(LOOCV) procedure to determine whether the overall
expression patterns of the 221 differentially regulated
gene probes could identify SIRS and sepsis classes. The
LOOCV procedure correctly predicted 86% of the SIRS
or sepsis classes. The top 100 class-predictor genes
(based on predictive strength) are provided in Addi-
tional file 1. Epstein-Barr virus-induced gene 3 (EBI3)
had the highest predictive strength.
Gene-expression mosaics of the top 100 class-predictor
genes
The expression values of the top 100 class-predictor genes
were uploaded to the GEDI platform, and reference gene-
expression mosaics were generated for patients with SIRS
and patients with sepsis, respectively (Figure 1A). The
reference mosaics represent the average expression pat-
terns for all patients in each class and demonstrate distinct
expression patterns for the patients with sepsis compared
with the patients with SIRS. Examples of individual patient
mosaics are provided in Figure 1B.
We next performed computer-assisted image analysis
to determine whether the expression mosaics could cor-
rectly identify SIRS and sepsis classes. The image-analy-
sis algorithm compared individual patient mosaics with
the two reference mosaics and assigned the individual
patients to either SIRS or sepsis classes, based on simi-
larity of expression [10]. The test characteristics of this
analysis are provided in Table 2. The expression mosaics
were able to identify patients with infection (sepsis) with
a high degree of specificity (90%) and a high positive
predictive value (94%). Thus, the top 100 class-predictor
genes represent a potential working list of candidate
diagnostic biomarkers for the presence of bacterial
infection in critically ill patients.
IL-27 as a diagnostic biomarker for bacterial infection in
critically ill patients
As previously noted, EBI3 had the highest predictive
strength for bacterial infection in this cohort of critically
ill children. EBI3 is a subunit of the heterodimeric cyto-
kine, IL-27, which is produced by antigen-presenting
cells and plays a role in regulating T-cell function [27].
Because IL-27 protein concentrations can be readily
measured in the serum compartment, we tested IL-27
serum protein concentrations as a diagnostic biomarker
for bacterial infection in critically ill children.
We measured IL-27 serum protein concentrations in
61 healthy control children and in a cohort of 231 criti-
cally ill children. One hundred and one critically ill chil-
dren met criteria for SIRS and had negative bacterial
cultures; 38 met criteria for sepsis and had positive bac-
terial cultures; and 92 met criteria for septic shock and
had positive bacterial cultures. All serum samples repre-
sent the first 24 hours of meeting clinical criteria for
SIRS, sepsis, or septic shock. The basic clinical and
demographic characteristics of this cohort, and the
Table 1 Clinical characteristics of the gene-expression
cohort
SIRS (n = 21) Sepsis (n = 60)
Median age in years 3.3 (2.0 to 8.3) 1.9 (0.6 to 5.1)a
Males (%) 52 67
Median PRISM score 10 (4 to 14) 14 (10 to 21)a
Mortality (%) 5 22
aP < 0.05 versus procalcitonin (PCT); PRISM, pediatric risk of mortality; SIRS,
systemic inflammatory response syndrome.
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respective median IL-27 concentrations, are shown in
Table 3. Patients with SIRS had significantly lower IL-27
serum protein concentrations compared with patients
with sepsis and patients with septic shock. Controls had
significantly lower IL-27 serum protein concentrations
compared with all classes of critically ill patients.
To determine the ability of serum IL-27 concentra-
tions to predict bacterial infection in critically ill
patients, we grouped the patients with sepsis and septic
shock as positive cases for infection, and compared
them with the SIRS patients as negative cases for infec-
tion. The area under the curve (AUC) for the receiver
operating characteristic (ROC) curve was 0.811 (0.755 to
0.868). The IL-27 test characteristics for predicting
infection in critically ill patients are provided in Table 4.
At a cut point of ≥5.0 ng/ml, serum IL-27 had a
specificity and positive predictive value of >90% for bac-
terial infection in this cohort of critically ill patients.
Collectively, these data indicate that serum IL-27 can
potentially serve as an effective “rule-in” test for bacter-
ial infection in critically ill patients.
Comparison with procalcitonin
Because procalcitonin (PCT) is currently being used
clinically as a biomarker for bacterial infection in criti-
cally ill patients, we also measured serum PCT concen-
trations in the same cohort of patients. As shown in
Table 3, patients with septic shock had significantly
higher PCT concentrations compared with patients with
SIRS or sepsis, but the PCT concentrations were not
significantly different between patients with SIRS and
patients with sepsis. PCT concentrations yielded an
AUC of 0.744 (0.680 to 0.808; P = 0.049 versus the
AUC for IL-27). The PCT test characteristics for pre-
dicting infection in critically patients are provided in
Table 5. These data demonstrate that IL-27 generally
performs better than PCT for predicting infection in
this cohort of critically ill patients.
Combining IL-27 and PCT
We next conducted CART analysis to determine whether
a combination of serum IL-27 and PCT concentrations
Figure 1 Reference and individual patient-expression mosaics for the top 100 class-predictor genes. (A) Gene Expression Dynamics
Inspector (GEDI)-generated reference mosaics for systemic inflammatory response syndrome (SIRS), and sepsis classes. Each reference mosaic
represents the average expression patterns of the top 100 class-predictor genes (see Additional File 1) for SIRS and sepsis classes, respectively.
(B) Examples of gene-expression mosaics for individual patients. Each example depicts the same top 100 class-predictor genes.
Table 2 Test characteristics of gene-expression mosaics
for identifying sepsis versus systemic inflammatory
response syndrome (SIRS)
% 95% Confidence interval
Sensitivity 53 39-66
Specificity 90 68-98
Positive predictive value 94 78-99
Negative predictive value 40 27-56
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could further improve the ability to predict infection in
critically ill patients [25]. The optimal decision tree gen-
erated by CART analysis is shown in Figure 2. The deci-
sion tree consists of two decision rules and three
terminal nodes. Subjects in terminal node 1 had a 19.4%
risk of infection. Subjects in terminal nodes 2 and 3 had
a 65.3% and a 90.9% risk of infection, respectively. To cal-
culate the global test characteristics of the decision tree,
we classified all subjects in terminal node 1 as “not
infected” and all subjects in terminal nodes 2 and 3 as
“infected.” This approach yielded an AUC of 0.846, a sen-
sitivity of 86% (79% to 91%), a specificity of 75% (65% to
83%); a positive predictive value of 82% (74% to 88%),
and a negative predictive value of 81% (71% to 88%). Col-
lectively, these data demonstrate that a combination of
IL-27 and PCT improves the overall ability to predict
infection in this cohort of critically ill patients, compared
with either biomarker alone.
Discussion
We previously reported differential patterns of gene
expression across the SIRS, sepsis, and septic-shock clin-
ical spectrum [14]. In that previous study, however, the
classifications of “sepsis” and “septic shock” were based
on either laboratory confirmation of a pathogen, or high
clinical suspicion of infection, according to published,
pediatric specific criteria [19]. The current analysis is
specifically targeted toward identification of patients
with signs of inflammation and laboratory confirmation
of a bacterial pathogen. Accordingly, all of the patients
in the current study who met criteria for sepsis and sep-
tic shock also had laboratory confirmation of a bacterial
pathogen.
Based on this analytic approach, we leveraged the dis-
covery potential of microarray-based transcriptomics
and generated a list of genes differentially regulated
between critically ill patients with SIRS (that is, patients
with sterile systemic inflammation) and critically ill
patients with sepsis (that is, patients with systemic
inflammation secondary to a documented bacterial
pathogen). This gene list represents a potential working
list of candidate diagnostic biomarkers for bacterial
infection in critically ill patients. The global expression
patterns of the top 100 class-predictor genes were able
to predict SIRS and sepsis classes with high specificity
and a high positive predictive value.
Generating gene-expression data and gene-expression
mosaics for 100 genes may not yet be clinically feasible
within the time-sensitive constraints of the intensive
care unit. Accordingly, we investigated the ability of
serum IL-27 protein concentrations to predict bacterial
infection in critically ill patients. The rationale for inves-
tigating IL-27 is based on the observation that EBI3 had
the highest predictive strength for bacterial infection of
all genes differentially regulated between patients with
SIRS and patients with sepsis. IL-27 is a heterodimeric
cytokine belonging the IL-6 and IL-12 family of cyto-
kines and is composed of the IL-27-p28 and EBI3 subu-
nits, which are produced by antigen-presenting cells on
exposure to microbial products and inflammatory sti-
muli [27]. IL-27 is a regulator T-cells, having both pro-
and antiinflammatory effects [28,29], and is rapidly
induced in a murine model of septic peritonitis [30].
Furthermore, genetic ablation of EBI3 or neutralization
of IL-27 via a soluble IL-27 receptor fusion protein is
protective in a murine model of septic peritonitis [30].
Table 3 Clinical characteristics of the interleukin-27 cohort
Controls (n = 61) SIRS (n = 101) Sepsis (n = 38) Septic shock (n = 92)
Median age in years 4.3 (1.2-6.5) 3.8 (1.2-6.4) 1.3 (0.4-5.3)a 2.4 (0.9-5.8)
Males (%) 57 58 58 64
Median PRISM score - 7 (2-11) 7 (5-13) 14 (8-21)b
Mortality (%) - 0 5 14c
Median IL-27 (ng/ml) 1.0 (0.7-1.6)d 2.5 (1.6-3.7)e 6.1 (3.6-9.5) 5.9 (3.2-10.9)
Median PCT (ng/ml) 1.3 (0.1-2.4) 1.8 (0.1-4.9) 6.1 (2.7-20.5)b
PRISM, pediatric risk of mortality; SIRS, systemic inflammatory response syndrome. aP < 0.05 versus Controls. bP < 0.05 versus SIRS and sepsis. cP < 0.05 versus
SIRS. dP < 0.05 versus SIRS, sepsis, and septic shock. eP < 0.05 versus sepsis and septic shock.
Table 4 Interleukin 27 (IL-27) test characteristics for predicting bacterial infection
Cut point ≥ (ng/ml) Sensitivity Specificity Positive predictive value Negative predictive value
2.0 92% (86-96) 35% (26-45) 65% (58-72) 78% (62-88)
3.0 79% (71-86) 60% (50-70) 72% (64-79) 69% (58-78)
4.0 69% (61-77) 82% (73-89) 83% (75-90) 67% (58-75)
5.0 61% (52-69) 92% (84-96) 91% (82-96) 64% (56-72)
6.0 51% (42-60) 96% (89-99) 94% (85-98) 60% (52-68)
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Thus, it is biologically plausible that IL-27 can serve as a
biomarker of bacterial infection in critically ill patients.
Serum IL-27 protein levels ≥5 ng/ml, obtained within
the first 24 hours of meeting clinical criteria for SIRS/
sepsis, had a high specificity and a high positive predic-
tive value for predicting bacterial infection in our cohort
of more than 200 critically ill patients with SIRS or sep-
sis. Thus, serum IL-27 has the potential to serve as an
effective “rule-in” test, given that concentrations ≥5 ng/
ml had a >90% specificity and positive predictive value
for bacterial infection in this cohort of critically ill
patients. Conversely, serum IL-27 protein concentrations
<5 ng/ml do not necessarily rule out bacterial infection,
given that the negative predictive value for a concentra-
tion ≥2 ng/ml was 78%. Finally, it does not appear that
increased IL-27 protein concentration in critically ill
children with bacterial infection reflects increased illness
severity, because the median IL-27 concentrations were
similar between patients with sepsis and patients with
septic shock.
PCT has emerged as a widely used diagnostic biomar-
ker for bacterial infection in clinical practice. However,
the performance of PCT varies depending on the patient
population in which it is applied, and a meta-analysis by
Tang et al. [1] concluded that PCT does not reliably dif-
ferentiate sepsis from noninfectious causes of SIRS in
critically ill adults. In our study population, PCT con-
centrations were not significantly different between
patients with SIRS and patients with sepsis; and IL-27
generally performed better than PCT as a diagnostic
biomarker based on the AUC and the test characteristics
calculated for various cut points.
Given the biologic complexity and heterogeneity of
critical illness, it is unlikely that any one biomarker will
consistently predict the presence of bacterial infection.
Accordingly, a strategy that combines diagnostic bio-
markers may perform better than any single biomarker
[2,31]. With a combination of IL-27 and PCT, we were
able to demonstrate an improved overall ability to both
“rule in” and “rule out” bacterial infection in this cohort
of critically ill patients.
Several strengths of our study design are worthy of
discussion. First, we selected IL-27 as a candidate diag-
nostic marker in an objective manner, by using the
Table 5 Procalcitonin (PCT) test characteristics for predicting bacterial infection
Cut point ≥ (ng/ml) Sensitivity Specificity Positive predictive value Negative predictive value
0.5 88% (81-93) 30% (21-40) 62% (55-69) 67% (51-80)
1.0 85% (77-90) 37% (28-47) 64% (56-71) 65% (51-77)
2.0 70% (61-78) 62% (52-71) 70% (62-78) 61% (51-71)
3.0 63% (54-71) 82% (73-89) 82% (73-89) 63% (54-71)
4.0 56% (47-65) 87% (78-93) 85% (75-91) 60% (52-68)
Figure 2 Classification and regression tree (CART)-generated decision tree combining IL-27 and procalcitonin (PCT) for the prediction
of bacterial infection in critically ill patients. Each node provides the total number of patients in either the sepsis ("Infected”) or systemic
inflammatory response syndrome (SIRS) ("Not Infected”) classes, and the respective rates. Each node also provides the decision rule based on
either an IL-27 or a PCT concentration cut point. The decision tree generated three terminal nodes having variable risks for infection.
Wong et al. Critical Care 2012, 16:R213
http://ccforum.com/content/16/5/R213
Page 6 of 8
discovery potential of transcriptomics. Second, our study
cohort was relatively large, and all patients in the sepsis
cohort had formal microbiologic confirmation of bacter-
ial infection. Third, the study cohort represents patients
from 17 different institutions. Finally, the serum IL-27
data reflect the first 24 hours of meeting criteria for
either SIRS or sepsis, which is a clinically relevant time
point for the prediction of bacterial infection in critically
ill patients.
Our study also has a number of limitations worthy of
discussion. First, although EBI3 mRNA levels had the
highest predictive strength, we did not directly measure
serum EBI3 protein concentrations, because it was tech-
nically more pragmatic to measure serum IL-27 concen-
trations. Second, EBI3 is also a subunit for IL-35, but
we were unable to measure serum IL-35 concentrations
for technical reasons. Third, we cannot exclude the pos-
sibility that some of the patients in the SIRS cohort had
bacterial infections that were undetectable by conven-
tional microbiologic cultures. Fourth, our data are lim-
ited to critically ill children and may not be
generalizable to other clinical settings. Finally, we have
no data regarding the temporal production of IL-27
during the course of bacterial infection. These limita-
tions provide further research opportunities for future
studies.
Conclusions
Genome-wide expression analysis has provided the foun-
dation for the identification of IL-27 as a novel candidate
diagnostic biomarker for predicting bacterial infection in
critically ill patients. We also demonstrated that a combi-
nation of IL-27 and PCT improves the overall ability to
predict infection, compared with that of either biomarker
alone. Additional studies will be required to test further
the diagnostic capabilities of IL-27.
Key messages
• By using microarray analysis, we identified 221 gene
probes that are differentially regulated between patients
with SIRS and patients with sepsis.
• The expression patterns of these differentially regu-
lated gene probes can distinguish patients with SIRS and
patients with sepsis with a high specificity and positive
predictive value.
• Epstein-Barr virus-induced gene 3 (EBI3), a subunit
of IL27, has the highest predictive strength among the
221 differentially regulated gene probes.
• Serum IL27 protein concentrations had a high speci-
ficity and positive predictive value for predicting bacter-
ial infection in a cohort of critically ill children.
• The performance of IL27 was generally superior to
that of procalcitonin in this cohort.
Additional material
Additional file 1: Top 100 class-predictor genes. A list of the top 100
predictor genes for bacterial infection
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